<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02525055</url>
  </required_header>
  <id_info>
    <org_study_id>RVL-003</org_study_id>
    <nct_id>NCT02525055</nct_id>
  </id_info>
  <brief_title>The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model</brief_title>
  <official_title>Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvivo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvivo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conducted an initial safety and characterisation study in healthy adult
      volunteers, utilising a unique clinical quarantine facility in London, UK.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Influenza and its associated diseases are a major cause of morbidity and mortality. The
      United States Advisory Committee on Immunization Practices recommends influenza vaccination
      for everyone over 6 months of age The failure of the flu vaccine in 2014-2015[ demonstrates
      the need for a model that allows the rapid development of novel antivirals,
      universal/intra-seasonal vaccines, immunomodulators, monoclonal antibodies and other novel
      treatments. To this end we manufactured a new H3N2 influenza virus in compliance with Good
      Manufacturing Practice for use in the Human Viral Challenge Model.

      The investigators chose an H3N2 influenza subtype, rather than H1N1, given that this strain
      has the most substantial impact in terms of morbidity or mortality annually as described by
      the Centre for Disease Control . The investigators first subjected the virus batch to
      rigorous adventitious agent testing, confirmed the virus to be wild-type by Sanger sequencing
      and determined the virus titres appropriate for human use via the established ferret model.
      We built on our previous experience with other H3N2 and H1N1 viruses to develop this unique
      model.

      Investigators conducted an initial safety and characterisation study in healthy adult
      volunteers, utilising our unique clinical quarantine facility in London, UK.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve of virus shedding</measure>
    <time_frame>12 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Infectious titre 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infectious titre 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infectious titre 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infectious titre 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infectious titre 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infectious titre 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infectious titre 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infectious titre 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infectious titre 1 (H3N2)</intervention_name>
    <description>Infectious titre 1</description>
    <arm_group_label>Infectious titre 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infectious titre 2 (H3N2)</intervention_name>
    <description>Infectious titre 2</description>
    <arm_group_label>Infectious titre 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infectious titre 3 (H3N2)</intervention_name>
    <description>Infectious titre 3</description>
    <arm_group_label>Infectious titre 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infectious titre 4 (H3N2)</intervention_name>
    <description>Infectious titre 4</description>
    <arm_group_label>Infectious titre 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Young healthy adults as determined by medical history, physical examination, serology
             (HIV and Hepatitis B and C) and clinical laboratory tests.

          -  Female subjects were required to provide of a history of reliable contraceptive
             practice.

        Exclusion Criteria:included;

          -  asthma,

          -  hypersensitivity to mercurials or chicken eggs,

          -  anatomic or neurologic abnormality impairing the gag reflex or contributing to
             aspiration, * chronic nasopharyngeal complaints,

          -  abnormal electrocardiogram (ECG),

          -  febrile illness or significant symptoms of upper respiratory infection on the day of

          -  Subjects using medication or other products for rhinitis or nasal congestion,

          -  Subject who had received systemic glucocorticoids within 1 month, or cytotoxic or
             immunosuppressive drugs within 6 months of the study start.

          -  Subjects agreed not to smoke during the quarantine phase.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan Muray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvivo</affiliation>
  </overall_official>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2015</study_first_posted>
  <last_update_submitted>August 13, 2015</last_update_submitted>
  <last_update_submitted_qc>August 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flu</keyword>
  <keyword>Influenza</keyword>
  <keyword>Human Viral Challenge Model</keyword>
  <keyword>Wild-Type</keyword>
  <keyword>H3N2</keyword>
  <keyword>H1N1</keyword>
  <keyword>Universal Influenza Vaccine</keyword>
  <keyword>intra-seasonal vaccines</keyword>
  <keyword>antiviral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

